Navidea Biopharmaceuticals, Inc.
Biotechnology ResearchUnited States11-50 Employees
Navidea is a leader in immuno-targeting, developing products based on its Manocept™ platform to help identify the sites and pathways of undetected disease and enable better diagnostic accuracy, clinical decision-making, targeted treatment and, ultimately, patient care. Lymphoseek®, Navidea’s first commercial product from the Manocept platform, was approved by the FDA in March 2013 and in Europe in November 2014. Applying our Manocept technology that is selective for immune cells called macrophages, Navidea seeks to develop next-generation targeted immunodiagnostics & immunotherapies for cancer, autoimmune conditions, and other inflammatory diseases. Our strategy is to deliver superior growth and shareholder return by bringing to market novel products and advancing the Company’s pipeline through global partnering and commercialization efforts.
1-888-653-2347 
support@leadiq.com 
